[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Optos, PLC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100604455","data-gathering-for-a10900-100604455",false,"NCT07149740","Data Gathering for A10900","Inclusion\u002FExclusion Criteria Inclusion Criteria for Retinal Disease Group\n\n1. Participants 22 years of age or older on the date of informed consent\n2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent\n3. BCVA 20\u002F400 or better in the study eye\n4. Participants presenting at the site with retinal disease\n5. Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration (including participants with drusen and geographic atrophy and choroidal neovascularization), Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Central Serous Retinopathy and others\n\nExclusion Criteria for Retinal Disease Group\n\n1. Participants unable to tolerate ophthalmic imaging\n2. Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons\n3. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study\n4. Presence of glaucoma or any ocular pathology other than a retinal pathology in the study eye as determined by self-report and\u002For investigator assessment at the study visit;\n\nInclusion Criteria for Glaucoma Group\n\n1. Participants 22 years of age or older on the date of informed consent\n2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent\n3. BCVA 20\u002F40 or better in the study eye\n4. History of Visual field defects within the previous year from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings:\n\n   1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;\n   2. Glaucoma hemi-field test \"outside normal limits.\"\n5. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:\n\n   1. Diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage;\n   2. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue\n\nExclusion Criteria for Glaucoma Group\n\n1. Participants unable to tolerate ophthalmic imaging\n2. Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons\n3. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study\n4. No reliable visual field test result within the previous year from the study visit, defined as fixation losses \\> 33% or false positives \\> 33%, or false negatives \\> 33% in the study eye\n5. Presence of any ocular pathology except glaucoma in the study eye Inclusion Criteria for Corneal Group\n\n1\\. Participants 22 years of age or older on the date of informed consent 2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Participants presenting at the site with corneal disease, for example but not limited to, corneal disorders due to contact lens wear, post-refractive surgery, dry eye, keratoconus 4. Participant is able to comply with the study procedures.\n\nExclusion Criteria for Corneal Group\n\n1. Participants unable to tolerate ophthalmic imaging\n2. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study\n3. Participant with ocular media not sufficiently clear to obtain acceptable OCT images.\n\nInclusion Criteria for Normal Group\n\n1. Participants 22 years of age or older on the date of informed consent\n2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent\n3. Participants presenting at the site with normal eyes (Cataracts, LASIK, PRK, and peripheral pathology that does not affect the posterior pole region, for example lattice and peripheral drusen, are allowed).\n4. BCVA 20\u002F40 or better (each eye)\n5. Participant is able to comply with the study procedures\n\nExclusion Criteria for Normal Group\n\n1. Participants unable to tolerate ophthalmic imaging\n2. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study\n3. Participant with ocular media not sufficiently clear to obtain acceptable OCT images\n4. History of leukemia, dementia or multiple sclerosis",true,"ALL","22 Years",{"count":19,"type":20},180,"ESTIMATED","OBSERVATIONAL","The objective of this study is to gather Optical Coherence Tomography (OCT) data on normal and diseased eyes",[24,25,26,27],"Retinal Disease","Healthy","Glaucoma","Corneal Diseases","RECRUITING","2026-02-11",{"date":31,"type":32},"2026-02-13","ACTUAL",{"date":34,"type":32},"2025-06-26",{"date":36,"type":20},"2026-05-01",{"name":38,"class":39},"Optos, PLC","INDUSTRY",4,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":15,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100581118","retinal-investigation-using-optos-oct-device-100581118","NCT06846151","Retinal Investigation Using Optos OCT Device","Clinical Investigation of Optos OCT in Patients with Retinal Pathologies","Inclusion Criteria:\n\n1. Male or female participants 18 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed.\n2. Participants who understand the study and patient information sheet and can follow the instructions.\n3. Participants who agree to participate in the study.\n4. Control group where no retinal abnormalities were detected as part of the standard basic ophthalmic examination.\n5. Participants with retinal disease in at least one eye including: Early dry age-related macular degeneration, late stage dry age-related macular degeneration specifically geographic atrophy, Wet age-related macular degeneration, Retinitis pigmentosa, Diabetic retinopathy and other macular atrophic diseases\n\nExclusion Criteria:\n\n1. Inability to understand written and verbal English sufficiently to comprehend the study and provide informed consent\n2. Ophthalmic disease other than condition under investigation.\n3. Participants unable to tolerate ophthalmic imaging.\n4. Cataract (unless deemed mild in the opinion of the investigator)\n5. Participants with significant ocular media not sufficiently clear to obtain acceptable OCT images.\n6. Diabetes (unless part of the diabetic eye disease group)\n7. Binocular visual acuity worse than 6\u002F18\n8. Strabismus (squint)\n9. Age related macular degeneration groups: polypoidal choroidal vasculopathy\n10. Participants with photo sensitivity epilepsy, experience of seizures, or sensitivity to flickering light (based on self-report)\n11. Pregnant","18 Years",{"count":50,"type":20},120,"INTERVENTIONAL",[53],"NA","Retinal investigation using OCT with control and diseased eyes",[56,57,58,59],"AMD - Age-Related Macular Degeneration","Retinitis Pigmentosa (RP)","Diabetic Retinopathy","Control Patients","NOT_YET_RECRUITING","2025-02-20",{"date":63,"type":32},"2025-02-25",{"date":65,"type":20},"2025-05",{"date":67,"type":20},"2026-01",{"name":38,"class":39},""]